Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians Who Treat Osteoporosis (US)

Analysis of: Drugs to Build Bones May Weaken Them (www.nytimes.com)
 Should bisphosphonates be stopped in patients who have been taking them for many years?  Should they be used at all?
Analysis of: Most Doctors Aren’t Using Electronic Health Records (www.nytimes.com)
Electronic Health Records (EHR) are like a marriage, but are difficult to implement.  They are expensive, time-consuming and require a paradigm shift from ALL employees of the practice.  Half of all attempts fail; similar to getting married.  They do save costs of transcription and filing/pulling...
May 28, 2008
Tekturna scripts
Analysis of: New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone (www.novartis.com)
I am a heavy user of ARB's and Tekturna.  This article does not really show anything of significance.  Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...
Analysis of: DXA Reimbursement Reductions: Implications for Quality Osteoporosis Care, Marjorie Luckey, MD and Roberta Biegel (Washington, DC: National Osteoporosis Foundation, Winter 2005) (osteoporosisblogger.com)
key implications: Less reimbursements for DEXA may lead to less testing, as cost of leasing equipment will be greater then revenue derived form procedures However, Less revenue/procedure could lead to greater utilization of equipment to cover costs involved and result in earlier testing of women...
Dipti Doshi, MD, Rheumatologist
HEALTHCARE PARTNERS MEDICAL GROUP
Analysis of: Trubion Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Rheumatoid Arthritis (www.pipelinereview.com)
Drug therapies for RA include (NSAIDS), DMARDS, and, most recently, biologics. Biologics currently on the market for RA target immune messengers called cytokines, which promote the damaging inflammatory process, and include anti-tumor necrosis factor (TNF) drugs – infliximab , etanercept,adalimumab,...
Charles Bennett, M.D., Radiation Oncologist
Charles Bennett, M.D., Radiation Oncologist
Robert Boissoneault Oncology Institute
Analysis of: A new player in the growing Breast Brachytherapy field (www.senorx.com)
SenoRx has released the Contura system which provides a superior system when compared to the Mammosite Breast Brachytherapy System.  These advantages include: 1.  Better dosimetry, opening the door for more patients to be treated by avoiding the elimination of some patients due to skin spacing...
Taral Patel, MD, Oncologist
Taral Patel, MD, Oncologist
Mid Ohio Oncology Hematology Inc.
February 19, 2008
Avastin In Breast cancer
Analysis of: In Second Trial, Avastin Is Found Effective in Treating Breast Cancer (www.nytimes.com)
New data with low and high dose of Avastin with Taxoter
Taral Patel, MD, Oncologist
Taral Patel, MD, Oncologist
Mid Ohio Oncology Hematology Inc.
Analysis of: Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival (www.pipelinereview.com)
esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...
Analysis of: Diabetes Study Partially Halted After Deaths (www.nytimes.com)
I beleive that this  announcement is premature and more about being too preacutious in the present litigenous environment. Sevral variable factors may responsible for the outcomes and not just the strict glycemic control.
Taral Patel, MD, Oncologist
Taral Patel, MD, Oncologist
Mid Ohio Oncology Hematology Inc.
December 7, 2007
Avastin in breast cancer
Analysis of: F.D.A. Criticizes Avastin Use for Breast Cancer (www.nytimes.com)
“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never...

Page : 1 2 3 4 Next1 to 10 of 38

Analytics


Generated at 2009-01-07T19:00:58.307